证券代码：603658 证券简称：安图生物 公告编号：2026-006 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 郑州安图生物工程股份有限公司（以下简称"公司"）于 2025 年 12 月 9 日召开第五届董事会第九次会议，审议通过了《关于使用闲置募集 资金进行现金管理的议案》，同意公司在确保不影响募集资金项目建设和 募集资金使用的情况下，公司拟分别使用不超过 1.4 亿元公开发行可转 换公司债券闲置募集资金和不超过15.4 亿元非公开发行股票闲置募集资 金进行现金管理，分别用于购买产品期限或剩余期限不超过 12 个月的结 构性存款、大额存单、国债逆回购、券商收益凭证、券商理财产品等安 全性高、流动性好的保本型产品。在上述额度范围内，资金可在 12 个月 内滚动使用。具体内容详见公司于 2025 年 12 月 10 日在上海证券交易所 网站（www.sse.com.cn）披露的《安图生物关于使用闲置募集资金进行 现金管理的公 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）及全 资子公司安图实验仪器（郑州）有限公司（以下简称"安图仪器"）于近日收到 河南省药品监督管理局颁发的医疗器械注册证，具体如下： 二、同类产品相关情况 证券代码：603658 证券简称：安图生物 公告编号：2026-005 郑州安图生物工程股份有限公司 关于公司及全资子公司获得医疗器械注册证的公告 郑州安图生物工程股份有限公司董事会 2026 年 2 月 12 日 根据国家药品监督管理局官网数据查询信息，截至公告日，国内外同行业部 分厂家已取得上述部分类似产品的医疗器械注册证。详情请登录国家药品监督管 理局（https://www.nmpa.gov.cn）查阅。 三、对公司的影响 上述医疗器械注册证的取得进一步丰富了公司产品菜单，不断满足市场需 编号 产品名称 注册证编号 注册证 有效期 预期用途 所属 公司 1 霉酚酸检测试剂盒（液 相色谱-串联质谱法） 豫械注准 20262400056 5 年 本产品用于体外定量 ...

内容概要：随着生物技术的飞速发展，数字PCR仪作为新一代的核酸检测技术，正逐渐在生命科学研 究、临床诊断、食品安全检测等领域崭露头角。数字PCR仪的出现，为核酸定量分析提供了更精确、更 灵敏的方法，弥补了传统PCR技术的一些局限性，被广泛认为是PCR技术发展的重要里程碑。在过去的 几年中，中国数字PCR仪市场规模呈现出稳健的增长态势。数据显示，2019-2025年中国数字PCR仪行 业市场规模从15.84亿元增长至88.15亿元，年复合增长率为33.1%。这一增长不仅得益于技术优势的驱 动，还得益于国家政策的支持。预计未来随着数字PCR仪的不断推广和应用，科研人员、临床医生以及 相关行业从业者对其优势和应用价值的认识逐渐加深，市场接受度不断提高，将进一步推动了市场需求 的增长。 相关上市企业：迈克生物（300463）、普门科技（688389）、科华生物（002022）、安图生物 （603658）、万孚生物（300482）、亚辉龙（688575）、美康生物（300439）、九强生物（300406）、 中源协和（600645）等。 相关企业：北京新羿生物科技有限公司、臻准生物科技（上海）有限公司、领航基因科技（杭 ...

Core Viewpoint - The company acknowledges that its stock price in the secondary market is influenced by multiple factors including industry policies, macroeconomic conditions, capital market supply and demand, and investor risk appetite [1] Group 1: Company Strategy - The company emphasizes the importance of stock price performance and shareholder concerns, indicating a commitment to addressing these issues [1] - The company plans to continue focusing on its core business, increasing research and development investment, and expanding its product line to enhance operational quality and core competitiveness [1] - The company aims to comprehensively layout in precision medicine and smart healthcare, while also strengthening market communication through compliant channels to protect the long-term interests of all shareholders [1]

（编辑 任世碧） 证券日报网讯 2月5日，安图生物在互动平台回答投资者提问时表示，截至目前，公司AI检验临床辅助 决策系统已在30余家医院安装，并顺利衔接医院现有检验设备及LIS系统，对公司毛利率影响较小。 ...

黄河之滨，天地之中。工业引擎轰鸣，新质生产力加速成长，正为郑州高质量发展注入澎湃动能。 最新统计数据显示，2025年，全市规上工业增加值同比增长9%，超七成行业生产实现增长。其中，电 子信息产业、汽车制造业增加值分别同比增长16.2%、11.9%，贡献突出。以宇通客车、安图生物、超 聚变等为代表的企业，在新能源、生物医药、先进算力等领域"向新而行"，勾勒出郑州工业结构升级、 韧性增强的清晰轨迹，夯实了实体经济根基。 全景扫描：稳中有进的数据版图 经济总量的跃升，源于关键领域扎实稳健的支撑。全市上下全力以赴推政策、扩需求，育新质、转 动能，坚持把保持工业经济快速增长态势作为经济发展压舱石。2025年，全市规上工业增加值同比增长 9%。规上工业38个行业大类中，27个行业增加值保持增长，增长面71.1%，比2024年提高8.9个百分 点。 主导产业拉动有力。规上工业主导产业增加值同比增长9.7%。其中，电子信息产业、汽车制造业 增加值分别同比增长16.2%、11.9%，合计拉动全市规上工业增加值增速6.4个百分点。 标杆力量：领军企业的奋进步履 在奋进前行的画卷中，领军企业是最具象、最生动的笔触。宇通客车、安图生 ...

Group 1: Nipah Virus Detection Products - Wanfu Biology announced the launch of "Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method)" to meet the demand for rapid and accurate testing [2] - Kehua Bio stated that its subsidiary has developed a Nipah virus detection kit to support key prevention and control points such as customs and disease control centers [3] - Zhijiang Biology emphasized the importance of early virus isolation and nucleic acid testing due to the non-specific symptoms in early-stage patients, offering a high-sensitivity detection kit [4] - Capbio has developed a Nipah virus detection kit, providing core technical support for global quarantine and disease control monitoring [4] - Shengxiang Biology offers a dual-platform solution for rapid and accurate detection of Nipah virus, with its detection kit already receiving EU CE certification [4] - Antu Biology provides rapid detection support through its fully automated nucleic acid purification and real-time fluorescent PCR analysis system [4] Group 2: Market Reactions and Clarifications - Some A-share companies clarified their positions, stating they do not have any business related to Nipah virus. Hualan Biological announced it has no vaccine products for Nipah virus [5] - Sely Medical confirmed it currently has no Nipah virus testing reagents or treatment drugs in reserve [6] - Other companies like Weixin Kang and CanSino also stated they do not have related products [7]

Core Viewpoint - The recent outbreak of Nipah virus in India has raised public concern, but experts believe it is unlikely to spread on a large scale like COVID-19 [1] Group 1: Company Developments - Multiple companies, including Antu Biology, Shuoshi Biology, Jinhao Pharmaceutical, Kaipu Biology, Zhijiang Biology, Zhongke Shengyi, Weiboxin Biology, and Shengke Yuan Biology, have developed nucleic acid testing reagents for Nipah virus and are actively supporting testing efforts [1] - There is reported procurement demand in relevant regions, although there have been no significant changes domestically; some key ports have a demand for reagent reserves [1] Group 2: Industry Insights - Experts, including Professor Jin Dongyan from the University of Hong Kong, suggest that Nipah virus is not a new virus and has caused small outbreaks with single-digit cases almost every year for the past two decades [1] - The current situation is not significantly different from previous years, and the virus has a low incidence of asymptomatic infections, allowing for effective control through isolation [1]

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

Group 1 - The recent outbreak of Nipah virus disease in West Bengal, India, has raised significant concern, with 5 confirmed cases reported, including healthcare workers, and nearly 100 individuals under home quarantine [1] - The impact of the Nipah virus outbreak on China is relatively minor, with no cases reported in the country, although there is a risk of imported cases that necessitates enhanced preventive measures [1][2] - Nipah virus has been known for over 20 years, with its first outbreak occurring in Malaysia in 1998, and it primarily affects South Asia and Southeast Asia [1][2] Group 2 - The Nipah virus primarily damages the central nervous system (90%) and respiratory system (62%), with a high fatality rate ranging from 40% to 75% [2] - Experts indicate that the Nipah virus has a low basic reproduction number (R₀) compared to influenza or COVID-19, and there have been no reports of large-scale airborne transmission [4] - Current antiviral treatments for Nipah virus are limited, with no approved drugs or vaccines available, although Ribavirin may be effective for treating Nipah virus encephalitis [4][5] Group 3 - Recent research has shown that VV116 has antiviral activity against Nipah virus in vitro and can improve survival rates in mouse models, indicating potential for treatment [4][5] - Several companies have reported possessing Nipah virus testing technology or products, but they have not yet achieved significant revenue from these offerings [6] - The most common testing method for Nipah virus is nucleic acid testing, and public health departments are equipped to handle such testing, which is deemed sufficient for current needs [6]